Publications

  1. Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2017 Oct 05 [Epub ahead of print]
    View PubMed
  2. Sinicrope FA, Shi Q, Alberts SR. Mutation in BRAF V600E-Reply. JAMA Oncol. 2017 Sep 01; 3 (9):1285-1286
    View PubMed
  3. Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouche O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Emile JF, Laurent Puig P, Sinicrope FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017 May; 109 (5) Epub 2016 Dec 31
    View PubMed
  4. Rashtak S, Rego R, Sweetser SR, Sinicrope FA. Sessile Serrated Polyps and Colon Cancer Prevention. Cancer Prev Res (Phila). 2017 May; 10: (5)270-278.
    View PubMed
  5. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 May 01; 28 (5):1023-1031
    View PubMed
  6. Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017 Apr 01; 3 (4):472-480
    View PubMed
  7. Miyoshi J, Toden S, Yoshida K, Toiyama Y, Alberts SR, Kusunoki M, Sinicrope FA, Goel A. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep. 2017 Mar 06; 7:43393
    View PubMed
  8. Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017 Feb 09;
    View PubMed
  9. Jansson-Knodell CL, Foster NR, Sargent DJ, Limburg PJ, Thibodeau SN, Smyrk TC, Sinicrope FA, Jahagirdar B, Goldberg RM, Alberts SR. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol. 2017 Feb; 8 (1):1-11
    View PubMed
  10. Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Mol Cancer Ther. 2016 Dec; 15: (12)3015-3027.
    View PubMed
  11. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 Dec; 21 (12):1509-1521 Epub 2016 Nov 23
    View PubMed
  12. Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. Int J Cancer. 2016 Oct 01; 139: (7)1626-31.
    View PubMed
  13. Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR, Alliance for Clinical Trials in Oncology. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Int J Cancer. 2016 Sep 01; 139 (5):986-95 Epub 2016 May 09
    View PubMed
  14. Sweetser S, Jones A, Smyrk TC, Sinicrope FA. Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair. Clin Gastroenterol Hepatol. 2016 Jul; 14 (7):1056-9 Epub 2016 Feb 17
    View PubMed
  15. Sinicrope FA. The role of microsatellite instability testing in management of colorectal cancer. Clin Adv Hematol Oncol. 2016 Jul; 14: (7)476-9.
    View PubMed
  16. Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol. 2016 May; 14: (5)651-8.
    View PubMed
  17. Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016 Apr 12; 7: (15)20080-92.
    View PubMed
  18. Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor abc294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells Oncotarget. 2016 Apr 12; 7: (15)20080-92.
  19. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
  20. Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. 2016 Feb; 65: (2)286-95.
    View PubMed
  21. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Algul H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, Banhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolome A, Bassham DC, Bassi MT, Bast RC Jr, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR Jr, Becker C, Beckham JD, Bedard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, Benard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, Bockler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouche M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Campbell M, et al, Chatterjee S, Chen CJ, Chen G, Chen H, Chen M, Chen Q, Chen W, Choi J, Dunn WA Jr, Fernandez-Zapico ME, Fiesel FC, Fisher PB, Her C, Hill WD, Hurley JH, Jackson DJ, Jackson WT, Jiang Y, Kumar D, Lee SJ, Lee YJ, Lerman LO, Lewis PA, Li L, Martin KR, McCormick C, Moore MN, Schulze RJ, Shi Y, Sinicrope FA, Springer W, Stevens C, Tang D, Wang XJ, Wang Y, Weyand CM, Williams K, Xiao J, Xu X, Zhang F, Zhang Y, Zhao X, Zhu W. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12 (1):1-222
    View PubMed
  22. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015 Dec 01; 21 (23):5294-304 Epub 2015 July 17
    View PubMed
  23. Kawakami H, Zaanan A, Sinicrope FA. Implications of mismatch repair-deficient status on management of early stage colorectal cancer. J Gastrointest Oncol. 2015 Dec; 6: (6)676-84.
    View PubMed
  24. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. Racial Differences in BRAFKRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst. 2015 Oct; 107: (10).
    View PubMed
  25. Zaanan A, Okamoto K, Kawakami H, Khazaie K, Huang S, Sinicrope FA. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. J Biol Chem. 2015 Sep 25; 290: (39)23838-49.
    View PubMed
  26. Zaanan A, Park JM, Tougeron D, Huang S, Wu TT, Foster NR, Sinicrope FA. Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer. 2015 Sep 15; 137: (6)1498-502.
    View PubMed
  27. Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, Buchanan DD, Casey G, Cleary SP, Cotterchio M, Farris AB, Figueiredo JC, Gallinger S, Green RC, Haile RW, Hopper JL, Jenkins MA, Le Marchand L, Makar KW, McLaughlin JR, Potter JD, Renehan AG, Sinicrope FA, Thibodeau SN, Ulrich CM, Win AK, Lindor NM, Limburg PJ. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24 (8):1229-38 Epub 2015 June 02
    View PubMed
  28. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015 Jul; 16: (7)30.
    View PubMed
  29. Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR, Goel A. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer. 2015 Jun 30; 113: (1)83-90.
    View PubMed
  30. Okamoto K, Zaanan A, Kawakami H, Huang S, Sinicrope FA. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. Mol Cancer Res. 2015 Apr; 13: (4)659-69.
    View PubMed
  31. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015 Jan; 148: (1)77-87.e2.
    View PubMed
  32. Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015 Jan; 148 (1):88-99 Epub 2014 Oct 08
    View PubMed
  33. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014 Dec; 106 (12) Epub 2014 Nov 07
    View PubMed
  34. Zaanan A, Bachet JB, Andre T, Sinicrope FA. Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAFV600E in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep. 2014 Sep 01; 10: (3)346-353.
    View PubMed
  35. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  36. Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 2014 Jun 15; 20: (12)3319-27.
    View PubMed
  37. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13 (2):100-9 Epub 2013 Dec 28
    View PubMed
  38. Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, Nair SG, Thibodeau SN, Goldberg RM, Sargent DJ, Sinicrope FA, Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014 Jun 01; 20 (11):3033-43 Epub 2014 Mar 31
    View PubMed
  39. Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014 Mar 1; 20: (5)1087-94.
    View PubMed
  40. Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 2014 Feb 1; 120: (3)415-24.
    View PubMed
  41. Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 2014 Jan; 99(1):60-9. Epub 2013 Aug 30.
    View PubMed
  42. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014 Jan; 232(2):199-209.
    View PubMed
  43. Graves KD, Sinicrope PS, Esplen MJ, Peterson SK, Patten CA, Lowery J, Sinicrope FA, Nigon SK, Borgen J, Gorin SS, Keogh LA, Lindor NM. Communication of genetic test results to family and health-care providers following disclosure of research results. Genet Med. 2014; 16(4):294-301.
    View PubMed
  44. Park JM, Tougeron D, Huang S, Okamoto K, Sinicrope FA. Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells. PLoS One. 2014; 9: (6)e100819.
    View PubMed
  45. Huang S, Okamoto K, Yu C, Sinicrope FA. p62sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregationactivation on the autophagosome. J Biol Chem. 2013 Nov 22; 288: (47)33654-66.
    View PubMed
  46. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013 Oct 10; 31: (29)3664-72.
    View PubMed
  47. Sinicrope FA, Smyrk TC, Tougeron D, Thibodeau SN, Singh S, Muranyi A, Shanmugam K, Grogan TM, Alberts SR, Shi Q. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013 Aug 1; 119: (15)2765-70.
    View PubMed
  48. Sweetser S, Smyrk TC, Sinicrope FA. Serrated colon polyps as precursors to colorectal cancer. Clin Gastroenterol Hepatol. 2013 Jul; 11: (7)760-7; quiz e54-5.
    View PubMed
  49. Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013 Apr 15; 119: (8)1528-36.
    View PubMed
  50. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013 Feb; 14: (2)100-7.
    View PubMed
  51. Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res. 2013 Jan 1; 73(1):160-71. Epub 2012 Nov 13.
    View PubMed
  52. Park JM, Huang S, Tougeron D, Sinicrope FA. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013; 8: (5)e65369.
    View PubMed
  53. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012 Nov 10; 30: (32)3932-8.
    View PubMed
  54. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 04; 307 (13):1383-93
    View PubMed
  55. et al, Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GC, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen YG, Chen YG, Chen YG, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Ding WX, Dong Z, Feng Y, Finley KD, Fisher EA, Fox HS, Gao FB, Gao GF, Gonzalez CD, Hansen M, Harris AL, Harris J, Hill JA, Huang J, Hurley JB, Hussain SN. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8: (4)445-544.
    View PubMed
  56. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15; 18(6):1506-12. Epub 2012 Feb 02.
    View PubMed
  57. Sinicrope PS, Goode EL, Limburg PJ, Vernon SW, Wick JB, Patten CA, Decker PA, Hanson AC, Smith CM, Beebe TJ, Sinicrope FA, Lindor NM, Brockman TA, Melton LJ 3rd, Petersen GM. A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev. 2012 Feb; 21: (2)347-50.
    View PubMed
  58. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012 Feb 01; 30: (4)406-12.
    View PubMed
  59. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope F. Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair. J Clin Oncol. 2012 Feb; 30: (4_suppl)460.
    View PubMed
  60. McWilliams RR, Mahoney MR, Sargent DJ, Nelson GD, Sinicrope F, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Alberts SR. A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. J Clin Oncol. 2012 Feb; 30: (4_suppl)446.
    View PubMed
  61. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18: (2)546-54.
    View PubMed
  62. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA. Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One. 2012; 7: (8)e42274.
    View PubMed
  63. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012; 10:205. Epub 2012 Oct 03.
    View PubMed
  64. Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. J Clin Oncol. 2011 Dec 1; 29: (34)4561-7.
    View PubMed
  65. Huang S, Yang ZJ, Yu C, Sinicrope FA. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1. J Biol Chem. 2011 Nov 18; 286: (46)40002-12.
    View PubMed
  66. Winawer SJ, Pasricha PJ, Schmiegel W, Sinicrope FA, Sung J, Seufferlein T, Kassem AM, Malekzadeh R, Kurtz RC, Classen M, Tytgat GN. The future role of the gastroenterologist in digestive oncology: an international perspective. Gastroenterology. 2011 Oct; 141(4):e13-21. Epub 2011 Aug 24.
    View PubMed
  67. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011 Sep; 10: (9)1533-41.
    View PubMed
  68. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011 Jun 08; 103: (11)863-75.
    View PubMed
  69. Sinicrope FA, Broaddus R, Joshi N, Gerner E, Half E, Kirsch I, Lewin J, Morlan B, Hong WK. Evaluation of difluoromethylornithine for the chemoprevention of Barrett's esophagus and mucosal dysplasia. Cancer Prev Res (Phila). 2011 Jun; 4(6):829-39.
    View PubMed
  70. Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. J Clin Oncol. 2011 May 20; 29: (15_suppl)3522.
    View PubMed
  71. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu T, Diasio RB, Jenkins RB, Sinicrope F. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol. 2011 May 20; 29: (15_suppl)4012.
    View PubMed
  72. Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. J Clin Oncol. 2011 May 20; 29: (15_suppl)3607.
    View PubMed
  73. Lewis M, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope F, Yoon HH. Association of body mass index (BMI) with smoking and prognosis in 721 patients with esophagogastric adenocarcinoma. J Clin Oncol. 2011 May 20; 29: (15_suppl)e14635.
    View PubMed
  74. Foster NR, Sinicrope F, Yothers GA, Allegra CJ, Sargent DJ. Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. J Clin Oncol. 2011 May 20; 29: (15_suppl)10590.
    View PubMed
  75. Sinicrope F, Foster NR, Yothers GA, Benson AB, Haller DG, Seitz J, Labianca R, Benedetti J, Goldberg RM, De Gramont A, Sargent DJ. Body mass index (BMI) as a prognostic and predictive factor in stage II/III colon cancer: An analysis of the ACCENT database. J Clin Oncol. 2011 May 20; 29: (15_suppl)e21126.
    View PubMed
  76. Borad MJ, Sigal D, Uronis H, Stephenson J, Bahary N, Rarick MU, DeMarco LC, Finnegan TJ, Chiorean EG, Ryan DP, Cohn AL, Ulrich BK, Harish VC, Anderes EN, Ma WW, Yu PP, Sinicrope F, Eng C, Sunkara UK, Reddy SG. Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. J Clin Oncol. 2011 May 20; 29: (15_suppl)TPS176.
    View PubMed
  77. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Future Oncol. 2011 Mar; 7: (3)467-74.
    View PubMed
  78. Huang J, Sargent DJ, Mahoney MR, Thibodeau SN, Smyrk TC, Sinicrope F, Nelson GD, Alberts SR. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. J Clin Oncol. 2011 Feb; 29: (4_suppl)363.
    View PubMed
  79. Sinicrope F, Benatti P, Foster NR, Marsoni S, Monges G, Labianca R, Yothers GA, Gallinger S, Sargent DJ. Detecting deficient DNA mismatch repair in stage II and III colon cancers. J Clin Oncol. 2011 Feb; 29: (4_suppl)419.
    View PubMed
  80. Yang ZJ, Chee CE, Huang S, Sinicrope F. Autophagy modulation for cancer therapy. Cancer Biol Ther. 2011 Jan 15; 11: (2)169-76.
    View PubMed
  81. Sugumar A, Sinicrope FA. Serrated polyps of the colon. F1000 Med Rep. 2010 Dec 17; 2:89.
    View PubMed
  82. Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clin Proc. 2010 Dec; 85: (12)1080-9.
    View PubMed
  83. Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am. 2010 Sep; 39: (3)601-13.
    View PubMed
  84. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10; 28: (20)3219-26.
    View PubMed
  85. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ, North Central Cancer Treatment Group. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer. 2010 Apr 01; 116: (7)1691-8.
    View PubMed
  86. Sinicrope FA, Foster NR, Sargent DJ, O'Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010 Mar 15; 16: (6)1884-93.
    View PubMed
  87. Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010 Mar 01; 70: (5)1960-9.
    View PubMed
  88. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7: (3)174-7.
    View PubMed
  89. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther. 2010 Mar; 9: (3)742-50.
    View PubMed
  90. Sinicrope FA. Opinion: DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2010 Mar; 7(3):174-7.
    View PubMed
  91. Huang S, Sinicrope FA. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 2010 Feb; 6: (2)256-69.
    View PubMed
  92. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2010 Jan 5; 102: (1)165-72.
    View PubMed
  93. Masuoka HC, Sinicrope FA. Clinical relevance of apoptotic regulatory proteins in colorectal cancers. Current Colorectal Cancer Reports. 2010; 6(3):111-7.
  94. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009 Oct; 137: (4)1270-9.
    View PubMed
  95. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol. 2009 Jul; 21: (4)369-73.
    View PubMed
  96. French AJ, Sinicrope F, Foster NR, Thibodeau SN, Sargent DJ, O'Connell MJ. Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers. J Clin Oncol. 2009 May 20; 27: (15_suppl)11093.
    View PubMed
  97. Sinicrope F, Foster NR, Sargent DJ, Alberts SR, O'Connell MJ. Prognostic impact of body mass index upon cancer recurrence and survival in stage III colon cancer patients from adjuvant chemotherapy trials. J Clin Oncol. 2009 May 20; 27: (15_suppl)11088.
    View PubMed
  98. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009 Jan 01; 15: (1)150-9.
    View PubMed
  99. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008 Dec 15; 14: (24)8132-42.
    View PubMed
  100. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res. 2008 Sep 15; 14: (18)5810-8.
    View PubMed
  101. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res. 2008 Jul 01; 14: (13)4128-33.
    View PubMed
  102. Sinicrope FA, Rego RL, Foster NR, Sargent DJ, Ansell SM, Kwon ED. Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers. J Clin Oncol. 2008 May 20; 26: (15_suppl)11023.
    View PubMed
  103. Rego RL, Smyrk TC, Foster NR, Sargent DJ, Thibodeau SN, Alberts SR, Windschitl HE, Sinicrope FA. Activated EGFR as a prognostic marker in human colon cancer. J Clin Oncol. 2008 May 20; 26: (15_suppl)22119.
    View PubMed
  104. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008 Apr 15; 68: (8)2944-51.
    View PubMed
  105. Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus. 2008; 21: (3)241-50.
    View PubMed
  106. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007 Jun 28; 251(2):237-46. Epub 2006 Dec 26.
    View PubMed
  107. Sinicrope FA, Rego RL, Garrity-Park MM, Foster NR, Sargent DJ, Goldberg RM, Wiesenfeld M, Witzig TE, Thibodeau SN, Burgart LJ. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer. 2007 Mar 15; 120: (6)1232-8.
    View PubMed
  108. Half E, Sinicrope FA. Current status of colorectal cancer chemoprevention. Current Colorectal Cancer Reports. 2007; 3(1):39-48.
  109. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN. Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol. 2006 Dec; 101: (12)2818-25.
    View PubMed
  110. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006 Sep; 131: (3)729-37.
    View PubMed
  111. Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):808-21. Epub 2006 Jun 22.
    View PubMed
  112. Rego RL, French AJ, Foster NR, Sargent DJ, Alberts SR, Windschitl H, O'Connell MJ, Thibodeau SN, Sinicrope FA. Epidermal growth factor receptor expression correlates with histologic grade but not microsatellite instability in primary colon carcinomas. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)20023.
    View PubMed
  113. Benson AB, Catalan P, Meropol NJ, Giantonio BJ, Sigurdson ER, Martenson JA, Whitehead RP, Sinicrope F, Mayer RJ, O'Dwyer PJ. ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3526.
    View PubMed
  114. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, Laplant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Thibodeau SN. Microsatellite instability but not thymidylate synthase is a prognostic variable in primary colon cancers from patients treated in 5-FU-based adjuvant studies. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)10019.
    View PubMed
  115. Sinicrope FA, Garrity M, Rego RL, French AJ, Foster NR, Sargent DJ, Goldberg RM, Laurie JA, Burgart LJ, Thibodeau SN, Witzig TE. Alterations in cell proliferation and apoptosis in human colon cancers with microsatellite instability. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)10022.
    View PubMed
  116. Cohen G, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, Yuan W, Obara P, Khare S, Sinicrope FA, Fichera A, Boss GR, Carroll R, Bissonnette M. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006 Jun 1; 66(11):5656-64.
    View PubMed
  117. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog. 2006 Jun; 45(6):447-54.
    View PubMed
  118. Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, Witzig TE, Thibodeau SN. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res. 2006 May 1; 12: (9)2738-44.
    View PubMed
  119. Yeung BH, Huang DC, Sinicrope FA. PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006 Apr 28; 281: (17)11923-32.
    View PubMed
  120. Sinicrope FA, Penington RC. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther. 2005 Oct; 4(10):1475-83.
    View PubMed
  121. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5 (3):211-3
    View PubMed
  122. Yeung B, Freeburg EN, Huang DT, Sinicrope FA. Bortezomib induces oxidative stress and apoptosis that are synergistically enhanced by a Bcl-2 inhibitor in human pancreatic cancer cells. J Clin Oncol. 2005 Jun; 23: (16_suppl)3161.
    View PubMed
  123. Sinicrope FA, Halling KC, French A, Burgart LJ, Foster N, Sargent DJ, Goldberg RM, O'Connell MJ, Witzig TE, Thibodeau SN. DNA ploidy is a stronger prognostic variable compared to microsatellite instability or 18q allelic loss in patients with stages II and III colon cancer. J Clin Oncol. 2005 Jun; 23: (16_suppl)9523.
    View PubMed
  124. Gill S, Sinicrope FA. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol. 2005 Feb; 32(1):24-34.
    View PubMed
  125. Sun Y, Sinicrope FA. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther. 2005 Jan; 4(1):51-9.
    View PubMed
  126. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res. 2004 Dec 15; 10(24):8284-92.
    View PubMed
  127. Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol. 2004 Dec; 12(4):350-5.
    View PubMed
  128. Freeburg EN, Sinicrope F. Small molecule Bcl-2 inhibitor enhances apoptosis induction by gemcitabine or sulindac sulfide in BxPC-3 pancreatic cancer cells. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)4256.
    View PubMed
  129. Penington R, Sinicrope F. Bcl-2 overexpression attenuates apoptosis induction by sulindac sulfide in SW480 human colon cancer cells. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3195.
    View PubMed
  130. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
    View PubMed
  131. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004 Feb 10; 108(4):540-8.
    View PubMed
  132. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Reviews. 2004 Jan-Jun; 23(1-2):63-75.
    View PubMed
  133. Sun YJ, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res. 2002 Nov 1; 62(21):6323-8.
    View PubMed
  134. Bismar MM, Sinicrope FA. Radiation enteritis. Curr Gastroenterol Rep. 2002 Oct; 4(5):361-5.
    View PubMed
  135. Tang XM, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002 Sep 1; 62(17):4903-8.
    View PubMed
  136. Sinicrope FA, Gwyn K. Chemoprevention of colorectal cancer. Am J Gastroenterol. 2002; 97:13-21.
    View PubMed
  137. Tatabe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, Kuo MT. Expression of heavy subunit of y-Glutamylcysteine synthetase (y-GCSh) in human colorectal carcinoma. Int J Cancer. 2002; 97:21-7.
    View PubMed
  138. Sample D, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2002; 11:281-5.
    View PubMed
  139. Sample D, Wargovich MJ, Fischer SM, Inamdar N, Schwartz P, Wang X, Do, K-A, Sinicrope FA. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal PGE2 levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 2002; 11:275-9.
    View PubMed
  140. Tatabe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance protein MRP1and MRP3 and y-glutamylcystein synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002; 290:1427-33.
    View PubMed
  141. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002; 62:1676-81.
    View PubMed
  142. Boland CR, Sinicrope FA, Brenner D, Carethers J. Colorectal cancer prevention and treatment. Gastroenterology. 2000; 118:S115-S28.
    View PubMed
  143. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa J-P. Aberrant methylation of the COX-2 CpG island in colorectal tumors. Cancer Res. 2000; 60:4044-8.
    View PubMed
  144. Frazier ML, Sinicrope FA, Amos CI, Cleary KR, Lynch PM, Luthra R. Loci for efficient detection of microsatellite instability in hereditary nonpolyposis colorectal cancer. Oncology Reports. 1999; 6:497-505.
    View PubMed
  145. Bold RJ, Hess KR, Pearson AS, Grau AM, Sinicrope FA, Jennings M, McConkey DJ, Bucana CD, Cleary KR, Chiao PJ, Abbruzzese JL, Evans DB. Prognostic factors in resectable pancreatic cancer: P53 and bcl-2. J Gastrointest Surg. 1999; 3:263-77.
    View PubMed
  146. Sinicrope FA, Hart J, Lemoine M, Michelassi F, Lee JJ, Stephens LC. Apoptotic and mitotic indices predict patient survival rates in lymph node-negative colon carcinomas. Clin Cancer Res. 1999; 5:1793-804.
    View PubMed
  147. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase-2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 1999; 117:350-8.
    View PubMed
  148. Molina M, Anja-Buta M, Lemoine M, Xi L, Frazier M, Sinicrope FA. Increased cyclooxygenase-2 expression in pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59:4356-62.
    View PubMed
  149. Sinicrope FA, Roddey GR, McDonnell TJ, Shen Y, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res 1996 06. 1999-20; 2:1999-2006.
  150. Sinicrope FA, Roddey GR, LeMoine M, Frazier M, Stephens LC, Shen Y, Zhang W. Loss of p21WAF1/Cip1 protein expression accompanies neoplastic progression in the sporadic colorectal cancers but not HNPCCs. Clin Cancer Res. 1998; 4:1251-61.
    View PubMed
  151. Sinicrope FA, Evans DB, Leach S, Cleary KR, Rich TA, Fenoglio C, Lee JJ, Abbruzzese JL. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996; 2:2015-22.
    View PubMed
  152. Sinicrope FA, Pazdur R, Levin B. Phase I evaluation of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy of colon carcinoma. Clin Cancer Res. 1996; 2:37-41.
    View PubMed
  153. Al-Sabbagh R, Sinicrope FA, Sellin J, Roubein L. Short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol. 1996; 91:1814-16.
    View PubMed
  154. Roubein LD, Lynch PM, Glober G, Sinicrope FA. Interobserver variability in endoscopic ultrasonography: a prospective evaluation. Gastrointest Endosc. 1996; 5:573-7.
  155. Sinicrope FA, Ruan S, Cleary KR, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55:237-41.
    View PubMed
  156. Sinicrope FA, Sugarman S. Role of adjuvant therapy in surgically resected colorectal carcinoma. Gastroenterology. 1995; 109:984-93.
    View PubMed
  157. Weber D, Dimopoulos M, Sinicrope FA, Alexanian R. VAD-cyclosporin therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1995; 19:159-63.
    View PubMed
  158. Sinicrope FA, Hart J, Michelassi FM, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995; 1:1103-10.
    View PubMed
  159. Sinicrope FA, Hart J, Michelassi F, Safa AR, Lee JJ, Brasitus TA. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer. 1994; 74:2908-17.
    View PubMed
  160. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1994; 10:610-17.
  161. Sinicrope FA, Sugarman SM. Adjuvant therapy of colon carcinoma: current status and future directions. Cancer Bull. 1994; 46:344-51.
  162. Sinicrope FA, Levin B. Gastric cancer. Curr Opin in Gastroenterol. 1993; 9:930-7.
  163. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P- glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem. 1992; 267:24995-5002.
    View PubMed
  164. Kavin H, Sinicrope FA, Esker AH. Perforation of the colon at endoscopy: a review. Am J Gastroenterology. 1992; 87:161-7.